<DOC>
	<DOCNO>NCT00121303</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cytarabine daunorubicin , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , gemtuzumab ozogamicin , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . It yet know whether cytarabine daunorubicin follow gemtuzumab ozogamicin effective cytarabine daunorubicin treat acute myeloid leukemia myelodysplastic syndrome . PURPOSE : This randomized phase III trial study cytarabine two different dos daunorubicin see well work compare cytarabine daunorubicin follow gemtuzumab ozogamicin treat old patient acute myeloid leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Cytarabine Daunorubicin With Without Gemtuzumab Ozogamicin Treating Older Patients With Acute Myeloid Leukemia Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare event-free disease-free survival old patient acute myeloid leukemia , refractory anemia excess blast ( RAEB ) , RAEB transformation treat induction therapy comprise cytarabine combination two different dos daunorubicin follow cytarabine alone without post-induction therapy comprise gemtuzumab ozogamicin . Secondary - Compare complete remission rate patient treat regimen . - Compare overall survival patient treat regimen . - Compare toxicity regimens patient . - Determine probability relapse death first complete remission patient treat post-induction gemtuzumab ozogamicin . - Correlate prognostic factor ( e.g. , CD33 positivity , multidrug resistance phenotype , cytogenetics ) probability complete remission overall , event-free , disease-free survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center diagnosis ( acute myeloid leukemia [ AML ] v myelodysplastic syndrome [ MDS ] ) induction therapy . Patients stratify accord participate center , diagnosis ( AML v MDS ) , induction treatment arm ( I vs II ) , response induction therapy ( complete remission [ CR ] v CR ) post-induction therapy . - Induction therapy ( course 1 ) : Patients randomize 1 2 induction treatment arm . - Arm I : Patients receive cytarabine IV continuously day 1-7 daunorubicin IV 3 hour day 1-3 . - Arm II : Patients receive cytarabine arm I daunorubicin arm I high dose . Approximately 28-35 day start course 1 ( sooner bone marrow show evidence resistant disease ) , patient arm proceed course 2 induction therapy . - Induction therapy ( course 2 ) : All patient receive cytarabine IV 6 hour twice daily day 1-6 . After completion course 2 , patient undergo assessment remission status . Patients achieve CR remove study . Patients achieve CR proceed post-induction therapy undergo second randomization . - Post-induction therapy : Patients randomize 1 2 post-induction treatment arm . - Arm I : Patients receive chemotherapy . - Arm II : Patients receive gemtuzumab ozogamicin IV 2 hour day 1 , 29 , 57 absence disease relapse unacceptable toxicity . After completion study treatment , patient follow monthly 1 year , every 3 month 2 year , every 4-6 month 2 year , periodically thereafter . PROJECTED ACCRUAL : A total 600 patient accrue study within 4-5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Gemtuzumab</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis 1 following : Acute myeloid leukemia ( AML ) M0M2 M4M7 FAB subtype No AML cytogenetic abnormality ( 15 ; 17 ) ( M3 ) Patients secondary AML progress prior myelodysplasia* biphenotypic leukemia eligible Refractory anemia excess blast ( RAEB ) RAEB transformation International Prognostic Scoring System score ≥ 1.5 NOTE : *Any prior hematological disease ≥ 4 month duration No chronic myelogenous leukemia blastic crisis No prior polycythemia rubra vera No primary myelofibrosis PATIENT CHARACTERISTICS : Age 61 Performance status WHO 02 Life expectancy Not specify Hematopoietic Not specify Hepatic ALT and/or AST ≤ 2.5 time upper limit normal ( ULN ) * Bilirubin ≤ 2 time ULN* NOTE : *Unless elevation cause organ infiltration AML Renal Creatinine ≤ 2 time ULN* NOTE : *Unless elevation cause organ infiltration AML Cardiovascular No myocardial infarction within past 6 month LVEF &gt; 50 % MUGA , echocardiogram , methods No unstable angina No unstable cardiac arrhythmia No severe and/or uncontrolled hypertension Other No uncontrolled diabetes No severe and/or uncontrolled infection No severe and/or uncontrolled medical condition PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy More 6 month since prior chemotherapy Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior induction therapy AML myelodysplastic syndrome</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>